Clinical Targeted Next-Generation Sequencing Panels for Detection of Somatic Variants in Gliomas
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Targeted next-generation sequencing (NGS) panels for solid tumors have been useful in clinical framework for accurate tumor diagnosis and identifying essential molecular aberrations. However, most cancer panels have been designed to address a wide spectrum of pan-cancer models, lacking integral prognostic markers that are highly specific to gliomas. Materials and Methods To address such challenges, we have developed a glioma-specific NGS panel, termed “GliomaSCAN,” that is capable of capturing single nucleotide variations and insertion/deletion, copy number variation, and selected promoter mutations and structural variations that cover a subset of intron regions in 232 essential glioma-associated genes. We confirmed clinical concordance rate using pairwise comparison of the identified variants from whole exome sequencing (WES), immunohistochemical analysis, and fluorescence in situ hybridization. Results Our panel demonstrated high sensitivity in detecting potential genomic variants that were present in the standard materials. To ensure the accuracy of our targeted sequencing panel, we compared our targeted panel to WES. The comparison results demonstrated a high correlation. Furthermore, we evaluated clinical utility of our panel in 46 glioma patients to assess the detection capacity of potential actionable mutations. Thirty-two patients harbored at least one recurrent somatic mutation in clinically actionable gene. Conclusion We have established a glioma-specific cancer panel. GliomaSCAN highly excelled in capturing somatic variations in terms of both sensitivity and specificity and provided potential clinical implication in facilitating genome-based clinical trials. Our results could provide conceptual advance towards improving the response of genomically guided molecularly targeted therapy in glioma patients.
Abstract
Purpose Targeted next-generation sequencing (NGS) panels for solid tumors have been useful in clinical framework for accurate tumor diagnosis and identifying essential molecular aberrations. However, most cancer panels have been designed to address a wide spectrum of pan-cancer models, lacking integral prognostic markers that are highly specific to gliomas. Materials and Methods To address such challenges, we have developed a glioma-specific NGS panel, termed “GliomaSCAN,” that is capable of capturing single nucleotide variations and insertion/deletion, copy number variation, and selected promoter mutations and structural variations that cover a subset of intron regions in 232 essential glioma-associated genes. We confirmed clinical concordance rate using pairwise comparison of the identified variants from whole exome sequencing (WES), immunohistochemical analysis, and fluorescence in situ hybridization. Results Our panel demonstrated high sensitivity in detecting potential genomic variants that were present in the standard materials. To ensure the accuracy of our targeted sequencing panel, we compared our targeted panel to WES. The comparison results demonstrated a high correlation. Furthermore, we evaluated clinical utility of our panel in 46 glioma patients to assess the detection capacity of potential actionable mutations. Thirty-two patients harbored at least one recurrent somatic mutation in clinically actionable gene. Conclusion We have established a glioma-specific cancer panel. GliomaSCAN highly excelled in capturing somatic variations in terms of both sensitivity and specificity and provided potential clinical implication in facilitating genome-based clinical trials. Our results could provide conceptual advance towards improving the response of genomically guided molecularly targeted therapy in glioma patients.
참고문헌 (30)
- Claes A, "Diffuse glioma growth : a guerilla war", Acta Neuropathol, 114, pp.443~458 (2007)
- Sahm F, "Farewell to oligoastrocytoma : in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma", Acta Neuropathol, 128, pp.551~559 (2014)
- Louis DN, "The 2016 World Health Organization classification of tumors of the central nervous system : a summary", Acta Neuropathol, 131, pp.803~820 (2016)
- Nikiforova MN, "Targeted next-generation sequencing panel(ThyroSeq)for detection of mutations in thyroid cancer", J Clin Endocrinol Metab, 98, pp.E1852~60 (2013)
- Kim J, "Spatiotemporal evolution of the primary glioblastoma Genome", Cancer Cell, 28, pp.318~328 (2015)
- Liu Q, "Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors", J Neurooncol, 94, pp.1~19 (2009)
- Cibulskis K, "Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples", Nat Biotechnol, 31, pp.213~219 (2013)
- Banerji S, "Sequence analysis of mutations and translocations across breast cancer subtypes", Nature, 486, pp.405~409 (2012)
- McLaren W, "Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor", Bioinformatics, 26, pp.2069~2070 (2010)
- Regnier MA, "Prognostic significance of blood lactate and lactate clearance in trauma patients", Anesthesiology, 117, pp.1276~1288 (2012)
- Fawcett T, "An introduction to ROC analysis", Pattern Recognit Lett, 27, pp.861~874 (2006)
- Gu Z, "Complex heatmaps reveal patterns and correlations in multidimensional genomic data", Bioinformatics, 32, pp.2847~2849 (2016)
- Zook JM, "Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls", Nat Biotechnol, 32, pp.246~251 (2014)
- Inda MM, "Glioblastoma multiforme : a look inside its heterogeneous nature", Cancers(Basel), 6, pp.226~239 (2014)
- Carr TH, "Defining actionable mutations for oncology therapeutic development", Nat Rev Cancer, 16, pp.319~329 (2016)
- Shen C, "Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel", Oncotarget, 7, pp.71686~71695 (2016)
- Hagemann IS, "Clinical next-generation sequencing in patients with non-small cell lung cancer", Cancer, 121, pp.631~639 (2015)
- Wang J, "Clonal evolution of glioblastoma under therapy", Nat Genet, 48, pp.768~776 (2016)
- Wang YY, "Mapping p53 mutations in low-grade glioma : a voxel-based neuroimaging analysis", AJNR Am J Neuroradiol, 36, pp.70~76 (2015)
- Stander M, "Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma : a long-term analysis", Cancer, 101, pp.1028~1035 (2004)
- Rogers TW, "The 2016 revision of the WHO Classification of Central Nervous System Tumours : retrospective application to a cohort of diffuse gliomas", J Neurooncol, 137, pp.181~189 (2018)
- Levidou G, "P53 immunoexpression as a prognostic marker for human astrocytomas : a meta-analysis and review of the literature", J Neurooncol, 100, pp.363~371 (2010)
- Verhaak RG, "Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1", Cancer Cell, 17, pp.98~110 (2010)
- Wee P, "Epidermal growth factor receptor cell proliferation signaling pathways", Cancers(Basel), 9, pp.E52~ (2017)
- Jenkins RB, "A t(1;19)(q10;p10)mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma", Cancer Res, 66, pp.9852~9861 (2006)
- Cairncross JG, "Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas", J Natl Cancer Inst, 90, pp.1473~1479 (1998)
- Brat DJ, "cIMPACT-NOW update 3 : recommended diagnostic criteria for"Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV"", Acta Neuropathol, 136, pp.805~810 (2018)
- Louis DN, "The 2007 WHO classification of tumours of the central nervous system", Acta Neuropathol, 114, pp.97~109 (2007)
- Kim ST, "Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials", Oncologist, 22, pp.1169~1177 (2017)
- 이호준, "Performance evaluation method for read mapping tool in clinical panel sequencing", Genes & Genomics, 40(2), pp.189~197 (2018), 한국유전학회[DOI]